AbCellera Biologics Hits Day High with 7.68% Surge in Stock Price

AbCellera Biologics, Inc. has experienced a significant uptick in its stock performance, gaining 7.68% on May 29, 2026. The stock reached an intraday high of USD 6.24, reflecting strong market activity. Over the past year, AbCellera has outperformed the S&P 500, delivering a remarkable return of 202.45% compared to the index's 28.21%. The company's recent financial results indicate a robust growth trajectory, with net sales increasing by 96.34% to USD 8.32 million. This growth is complemented by a notable reduction in raw material costs, which fell by 91.06% year-over-year. Despite these positive indicators, the company reported a net profit of USD -52.91 million for the half-year, highlighting ongoing challenges. AbCellera's institutional holdings stand at 54.64%, suggesting a solid backing from investors with the resources to analyze the company's fundamentals. The stock's performance over the past month and week has also been impressive, with gains of 61.52% and 18.65%, respectively, further solidifying its position in the pharmaceuticals and biotechnology sector.